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• cAng-(1-7) improves neurological severity score 
• cAng-(1-7) improves performance in the stepping and forelimb placement tests  
• cAng-(1-7) improves performance in the body swing test  




Peptidase-resistant, lanthionine-stabilized angiotensin-(1-7), termed cAng-(1-7), has 
shown therapeutic efficacy in animal models of cardiovascular, metabolic, kidney and 
pulmonary disease. Goal of the present study was testing the capacity of subcutaneously 
administered cAng-(1-7) to induce rehabilitation of animal performance in the transient 
middle cerebral artery occlusion rat model of cerebral stroke. 24 hours after ischemic 
stroke induction, cAng-(1-7) was administered for 28 days at a dose of 500 µg/kg/day, 
either daily via subcutaneous injection or continuously via an alzet pump. Both ways of 
administration of cAng-(1-7) were equally effective. Measurements were continued until 
day 50. Compared to vehicle, cAng-(1-7) clearly demonstrated significantly increased 
capillary density (p<0.01) in the affected hemisphere and improved motor and 
somatosensory functioning. The modified neurological severity score (p<0.001 at days 15 
and 50), stepping test (p<0.001 at days 36 to 50), forelimb placement test (p<0.001 at day 
50), body swing test (p<0.001 at days 43 and 50) all demonstrated that cAng-(1-7) caused 
significantly improved animal performance. Taken together the data convincingly 
indicate rehabilitating capacity of subcutaneously injected cAng-(1-7) in cerebral 
ischemic stroke. 
 














Cerebral ischemic stroke is a prominent cause of serious, long-term disability and the second 
leading cause of death worldwide. Ischemic stroke, initiated by occlusion of brain vessels, and 
hemorrhagic stroke account for, respectively, 80% and 20% of the cerebrovascular accidents. 
The only FDA-approved treatment for acute ischemic stroke is intravenously administered 
tissue plasminogen activator. Unfortunately, its therapeutic window is limited to the first three 
hours of symptom onset, and it confers risk of bleeding. Hence, new treatments for stroke are 
needed.  
Hypertension is a risk factor for the occurrence of stroke [3]. Arterial pressure and 
cardiovascular disease are largely controlled by the renin-angiotensin system (RAS). The 
heptapeptide Ang-(1-7) is a key factor of the protective arm of this system and exerts, next to 
cardiovascular roles, many other therapeutic effects. However, Ang-(1-7) is rapidly degraded 
by ACE and other peptidases. Upregulation of the angiotensin converting enzyme 2 (ACE2) / 
angiotensin-(1-7) (Ang-(1-7)) pathway has broad therapeutic potential in stroke [3,36,49].  
In contrast to natural Ang-(1-7), lanthionine-stabilized cAng-(1-7), shows resistance to 
peptidases and is fully resistant to ACE. Its prolonged half-life in vivo allows pulmonary 
delivery. CAng-(1-7) demonstrated therapeutic efficacy in animal models of, amongst others, 
myocardial infarction, lung fibrosis, neonatal lung injury, pulmonary arterial hypertension, 
kidney disease and type 1 and 2 diabetes mellitus [7,21,23]. 
In this study, we tested cAng-(1-7) for the first time in the transient middle cerebral 
artery occlusion (tMCAO) rat stroke model. Therapeutic efficacy of cAng-(1-7) was assessed 
by the following analyses: modified neurological severity score, stepping test, forelimb 
















4,7 D,L lanthionine-stabilized angiotensin-(1–7) peptide (cAng-(1–7)) was synthesized as 
previously [23]. In preliminary experiments (data not shown), daily subcutaneous 
administration by alzet pump of 50 µg/kg/d and 500 µg/kg/d of cAng-(1–7) was applied. The 
dose of 500 µg/kg/d, used in this study, gave overall a slightly better effect. As vehicle, DPBS 




Male Sprague-Dawley (SD) rats with an average body weight of 314 g at study initiation (day 
1) were obtained from Harlan Laboratories (Israel) and were housed in polyethylene cages 
(5/cage), measuring 35 × 30 × 15 cm. Rats were housed under standard laboratory conditions, 
with adequate fresh air supply, a photo cycle of 12 h of light and 12 h of dark and at ambient 
temperature of 20–24 0C. Animals were fed ad libitum on a commercial rodent diet (Teklad 
Certified Global 18% Protein Diet cat #: 106S8216) and had free access to autoclaved and 
acidified drinking water (pH 2.5 - 3.5). Male rats were used in this study with the purpose to 
reduce the variability within the groups due to gender, and avoid the female hormonal cycle. 
The studies were performed at Pharmaseed Ltd. (Israel) and animal handling was 
performed according to guidelines of the National Institute of Health (NIH) and the Association 
for Assessment and Accreditation of Laboratory Animal Care (AAALAC). The study was 










"The Israel Board for Animal Experiments". 
 
2.3. tMCAO occlusion 
 
On the day of surgery, anesthesia was induced by 4% isoflurane in a mixture of 70% N2O and 
30% O2 and maintained with 1.5-2% isoflurane. Transient middle cerebral artery occlusion 
(tMCAO) was performed in which the mid cerebral artery of the right hemisphere was 
occluded. The tMCAO procedure day is defined as "day 1". A 4-0 monofilament nylon suture, 
coated with polylysine of 4 cm length was used for the occlusion. The surgical wound was 
closed and the animals were returned to their cages to recover from anesthesia. Two hours after 
occlusion rats were re-anesthetized, monofilament was withdrawn to allow reperfusion, the 
surgical wound was closed and rats were returned to their cages.  
Animals were subjected to a modified Neurological Severity Scale (mNSS) test at 24 
hours post reperfusion for exclusion criteria. Rats were stratified to the various groups 
according to the Neuro-Score results, in order to get even groups with similar stroke severity. 
Ten rats died following stroke induction and were not used. No animals were excluded due to 
neuroscore criterion. Only animals with an overall score of  ≥ 10 were kept included in the 
study [8]. For all the behavioural tests, the individual who performed the tests was blinded as 
to the type (vehicle/drug/dose) of the treatment. 
 
2.4. Administration of cAng-(1-7)  
 
Animals in the vehicle-injected group and in the cAng-(1-7)-injected group received daily 
subcutaneous injections of, respectively, vehicle or 500 µg/kg/d cAng-(1-7) starting on day 2, 











an osmotic alzet pump was implanted subcutaneously for continuous administration of 500 
µg/kg/d cAng-(1-7) during 28 days. After the evaluation with the neuroscore for exclusion 




Death was recorded daily; the dead animal was excluded from the study. 
 
2.6. Body weight 
 
Body weight was measured on days 1, 2 and weekly thereafter, using a laboratory balance.  
 
2.7. Neurological test score 
 
The Modified Neurological Severity Scale (mNSS) analysis, including a set of clinical-
neurological tests such as the composite of motor -, sensory -, reflex and balance tests, was 
applied. The neurological severity scale with a total score 18 was used [8]. 
 
2.8. Stepping test 
 
Animals were tested with respect to forelimb akinesia using the stepping test. The animal was 
held with its hind limbs and one forelimb fixed with one hand and the unrestrained fore-paw 
was drawn along the table. The number of adjusting steps was counted while the animal was 
moved sideways along the table surface, 85 cm in approximately five seconds, in the forehand 












2.9. Forelimb placing 
 
For the forelimb-placing test, the examiner, blinded to treatment assignment, held the rat close 
to a tabletop and scored the rat's ability to place the forelimb on the tabletop in response to 
whisker, visual, tactile, or proprioceptive stimulation. Separate sub-scores were obtained for 
each mode of sensory input and added to give total scores (0 = normal, 12 = maximally 
impaired). Accordingly, the forelimb placing test score (0-12) was composed of the following 
scores: whisker placing (0-2); visual placing (forward (0-2), sideways (0-2)); tactile placing 
(dorsal (0-2), lateral (0-2)); proprioceptive placing (0-2). For each subtest, animals were scored 
as follows: 0.0 = immediate response; 0.5 = response within 2 seconds; 1.0 = response of 2-3 
seconds; 1.5 = response of > 3 seconds; 2.0 = no response [17]. 
 
2.10. Body swing test 
 
The body swing test was performed as described [5]. The rat was held approximately one inch 
from the base of its tail. It was then elevated to an inch above a surface of a table. The rat was 
held in the vertical axis, defined as no more than 10° to either the left or the right side. A swing 
was recorded whenever the rat moved its head out of the vertical axis to either side. Before 
attempting another swing, the rat was returned to the vertical position for the next swing to be 
counted. Twenty total swings were counted. A normal rat typically has an equal number of 
swings to either side. Following focal ischemia, the rat tends to swing to the contralateral side, 
which is the left side here. Body swing scores were expressed as delta left turn - right turn.  
 












On day 51 or 52 after stroke induction, all rats from the s.c.-injected vehicle group and the s.c.- 
injected cAng-(1-7) group (500 μg/kg/d) were anesthetized by ketamine/xylazine, 
transcardially perfused by paraformaldehyde solution and three sections of brain samples were 
taken from the same areas of all animals. The sections were taken from the parietal lobe brain 
region at the infarct area, between -1.8 mm to -2.3 mm relative to Bregma (according to Paxinos 
Atlas). The sections were stained for immunohistochemical analysis by Smooth Muscle Actin 
(SMA) and Factor 8 antibodies (Thermo Fisher Scientific, Cheshire UK). For the SMA 
antibody, the kit’s instructions were followed and the histology slides were incubated with the 
antibody for 20 minutes at room temperature. For the Factor 8 antibody, slides were incubated 
with the antibody in 2% normal horse serum in PBS, for 30 minutes at 37 C. On the next day, 
after three washes with PBS, slides were incubated with biotinylated (AP)-conjugated 
secondary antibody for one hour at RT. Capillaries were identified under the microscope 
(Olympus BX43 with x10 magnification) in a total of three random fields from each section 
and photographed with high-resolution camera connected to a computer. Vascular density 
count was performed by using Image analysis software mainly used  - Image Pro Plus Ver. 5.1 
by Media Cybernetics. (+ optional software  -  Image Scope by Aperio, USA + Image-J by 




Data are presented as the mean with standard error (SEM). Statistical analysis was performed 
by two-way ANOVA for repeated measures, followed by Bonferroni post hoc tests or, in Fig 
6E, by an unpaired t-test. Calculations were performed using GraphPad Prism 8.1.1 software 











asterisks in the figures and corresponding p values in the legends, were considered significant 







In the s.c.-injected vehicle group of 14 rats, one rat died after the first dosing. No rats from 
either the s.c.-injected cAng-(1-7) or alzet pump-administered cAng-(1-7) died during the 
treatment.  
 
3.2. Body Weight 
 
Throughout the study, no statistically significant differences in body weight were observed 
among any of the different groups of animals (Fig. 1). 
 
3.3. Neurological test score 
 
As expected, in all groups of rats a sharp decline in neurological score was observed 24 hours 
after tMCAO followed by spontaneous improvement over time thereafter. However, a clear 
neurological improvement was observed at study day 15 and lasted up to at least day 50 in both 
cAng-(1-7)-treated groups compared to vehicle treated control (Fig. 2). 
 












Animals were also tested with respect to forelimb akinesia in a stepping test, commonly used 
for measurement of neuromuscular functions, as an index for motoric functioning of the animal. 
Spontaneous improvement in motor function over time was observed in all animals that were 
subjected to tMCAO. However, functional improvement in rats treated with cAng-(1-7) was 
more pronounced compared to vehicle-treated control. For alzet-pump-administered cAng-(1-
7) and for s.c.-injected cAng-(1-7) this improvement reached statistical significance compared 
to vehicle on days 22 and 29, respectively, which lasted up to at least day 50 (Fig. 3). 
 
3.5. Forelimb placement test score 
 
A forelimb placement test was applied to measure somatosensory and sensory motor deficits. 
Similar to other tests spontaneous improvement in sensory motor deficit over time was 
observed in all animals that were subjected to tMCAO. There was additional functional sensory 
motor improvement in all rats that were cAng-(1-7)-treated compared to vehicle-treated 
control. This statistically significant improvement was more pronounced in treated animals 
from both groups on days 36-50 (Fig. 4). 
 
3.6. Body swing test score 
 
Animals were also tested for forelimb akinesia in a body swing test, commonly used for 
measurement of neuromuscular functions. CAng-(1-7) subcutaneously injected or 
administered by alzet pump clearly enhanced the recovery with respect to forelimb akinesia 
and reached statistical significance, compared to vehicle treated control, at day 29 which 












3.7. CAng-(1-7) caused an increase in the number of capillaries 
 
Animals, except the alzet-administered cAng-(1-7) group, were examined in case of treatment 
with cAng-(1-7) (500 μg/kg/d, s.c., n=14) compared to treatment with vehicle (s.c., n=13). 
Treatment with cAng-(1-7) increased the number of capillaries evaluated by immunostaining 




The RAS system may play a role in cerebral stroke and enhanced signaling via its AT1 receptor 
(AT1R) of centrally delivered angiotensin II can provoke ischemic stroke and neuronal damage 
[44]. Inhibition of this axis by the use of peripherally delivered ACE inhibitors (<500 Da) 
showed neuroprotection in rodents with focal cerebral ischemia [10]. ACE inhibitor captopril-
induced elevation of Ang-(1-7) levels caused neuroprotection in rat cerebral ischemia [45]. 
Counterbalancing of the ACE / Ang II / AT1R axis by the protective ACE2 / Ang-(1-7) 
pathway resulted in neuroprotection in stroke models [3]. Ischemic cerebral stroke itself caused 
in rats increased levels of ACE2 and Ang-(1-7) [32]. Overexpression of ACE2 led to brain 
protective effects [9,50,51]. Intracerebroventricular infusion of an ACE2 activator significantly 
attenuated the cerebral infarct size and neurological deficits [33]. In vitro, Mas receptor agonist 
AVE 0991 exerted direct protective effects on neuronal cells [27]. Intranasal delivery of AVE 
0991 attenuated neuronal apoptosis via the MasR/PKA/CREB/UCP-2 pathway after 
hemorrhage in rat [34].  
Natural Ang-(1-7) has been suggested to act in vivo via the Mas receptor [42]. The 










[15,18,19,33,39]. Moreover, the anti-inflammatory effects caused by Ang-(1-7) were not 
reversed by PD123319, an angiotensin II type 2 receptor antagonist [18]. A recent in vitro study 
showed that Ang-(1-7) amplified MasR-induced negative modulation of cAMP levels and 
suggested that discrepancies with other in vitro studies [13,46,47] might be due to differences 
in experimental design [6]. Ang-(1-7) might also act as AT1-R-biased agonist, selectively 
promoting β-arrestin activation while blocking the unfavorable Ang II/AT1-R/Gq axis [14]. In 
addition, Mas/AT1 receptor heterodimerization [22] and / or Mas/AT2 receptor 
heterodimerization [28] urge to more than usual prudence in the interpretation of Mas receptor 
specificity and activation in both in vitro and in vivo studies.  
Significant cerebroprotective actions of intracerebroventricularly administered Ang-
(1–7) (899 Da) have been clearly demonstrated in many studies [1,18,19,33,39,40]. Cerebral 
stroke may initially cause BBB dysfunction (20). Therefore it can not be excluded that cAng-
(1-7) passes the BBB early after the stroke induction. Intracerebrally administered Ang-(1-7) 
exerts protective effects on the BBB integrity, which may contribute to recovery after cerebral 
stroke, by regulating the tight junction protein expression [30,48]. Restoration of BBB integrity 
importantly contributes to reducing stroke-related neurological damage [2]. 
Interestingly, an orally delivered cyclodextrin-formulated Ang-(1-7) reduced in 
cerebral infarct volume and improved neurological functions. The authors speculated that Ang-
(1-7) might pass the BBB that might be compromised during stroke [4]. In healthy rats, some 
intravenously injected natural Ang-(1-7) (899 Da) and more of the glucosylation-stabilized 
Ang-(1-7) (1278 Da) could be retrieved from cerebrospinal fluid [16], however, no mechanism 
of BBB passage was proposed and the used dosage of 10 mg/kg was high.  
The BBB protects the central nervous system and limits the entry of, not only harmful 











nose-to-brain delivery of peptides is being investigated as an alternative route. CAng-(1-7) 
does not comprise a transport-specific ligand that would allow transport across the BBB. It is 
larger than the common upper limit of 500 Da for passive permeation across a membrane. 
CAng-(1-7) is very hydrophilic with high hydrogen bonding potential and –although cyclized- 
definitely lacks the lipophilicity that would facilitate crossing the BBB by diffusion [11,26]. 
Consistent with difficult delivery across the BBB, natural Ang-(1-7) has been administered by 
intracerebral infusion in many studies [1,18,19,30,33,39,40,48]. In essence, the efficient 
delivery of peptides across the intact BBB to the brain requires invasive techniques. It has been 
recognized that the major hurdle in exploiting the ACE2/Ang-(1–7) cerebroprotective axis is 
to find post-stroke treatments that can be administered non-invasively [38]. Peptides that may 
exert important cerebroprotective action after peripheral s.c. administration, like observed in 
the present study, are therefore clearly of special interest.  
CAng-(1-7) activity was abolished or reduced by the Ang-(1-7) receptor antagonist D-
Pro7/D-Ala7 [21]. CAng-(1-7) and Ang-(1-7) stimulate the proliferation of endothelial 
progenitor cells in the bone marrow [41,43]. After stroke bone-marrow-originating endothelial 
progenitor cells migrate to the injured area to contribute to vascular remodeling and 
angiogenesis. They can interact with endothelial cells, extravasate, and reach the injured site, 
where they incorporate into the vascular wall thus repairing endothelial damage occurring in 
stroke. They also produce trophic factors supporting neuroprotection. In stroke, angiogenesis 
and neurogenesis are coupled by signaling from exosomes [2,12]. CAng-(1-7) clearly caused 
significant increase in capillary density. A previous study on natural intracerebrally 
administered Ang-(1-7) demonstrated that administration prior to stroke induction promotes 
endothelial cell proliferation and increases brain capillary density [19]. Li et al demonstrated 
that cerebral capillary density supports health after ischemia [29]. Accordingly, patients with a 











capillary density [24]. Furthermore cAng-(1-7) might improve vasodilatory capacity [25,31], 
exert anti-inflammatory effects [18] and/or stimulate brain-derived neurotrophic factor [37].   
The rat stroke tMCAO model is a traditionally accepted model for screening and 
evaluation of neuroprotective and rehabilitative treatments. In this study, cAng-(1-7) clearly 
and significantly improved motor functions evaluated by neuroscore, stepping test and body 
swing test. Sensory motor functions were also sensitive to the treatment with cAng-(1-7) 
witnessed by the forelimb placement test. The effect of cAng-(1-7) reached its highest 
significance in the period of day 29 to 50. In this rat model administered at a dose of 500 
µg/kg/d, cAng-(1-7) exerted a comparable effect when administered continuously via the alzet 
pump or when injected. Taken together these data indicate that rehabilitation of performance 
found in the present study might result from enhanced Mas receptor stimulation. 
CAng-(1-7) has strongly enhanced resistance to peptidase-mediated breakdown [21]. 
Taken together with the data in the current study, further studies on the therapeutic capacity of 
this cyclized angiotensin-(1-7) receptor agonist may be of interest. It will be important to assess 
whether or not the therapeutic potential of this receptor agonist differentiates from AT1R 




It can be concluded that under the conditions of the present study, subcutaneously administered 
cAng-(1-7) treatment clearly improved the animal performance with respect to motor and 
somatosensory deficits in the rat stroke model. Furthermore, cAng-(1-7) significantly increased 
capillary density. Taken together, cAng-(1-7) is of interest as potential treatment for recovery 
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LEGENDS TO THE FIGURES 
 
Fig. 1. CAng-(1-7) did not alter body weight of rats after stroke. 
cAng-(1–7) (500 µg/kg/d) subcutaneously injected (n=14) or administered by alzet pump 
(n=14) does not significantly alter body weight, when compared with vehicle (n=13). Data are 
presented as means ± SEM. 
 
Fig. 2. CAng-(1-7) significantly improves the neuroscore after stroke.  
After stroke induction, rats were treated with s.c.-injected vehicle or with subcutaneously 
injected cAng-(1-7) (500 μg/kg/d) or with alzet pump-administered cAng-(1-7) (500 μg/kg/d). 
Modified neurological severity scale data, up to a score of 18, which represents the most severe 
neurological situation, are presented as means + SEM. There were no significant differences 
between the cAng-(1-7) treated groups. Statistically significant differences of each cAng-(1-7) 
group compared to vehicle are indicated by asterisks in the figure, *p < 0.05; ** p < 0.01; *** 
p < 0.001.  
 
Fig. 3. CAng-(1-7) reduces forelimb akinesia after stroke.  
Stepping test data are presented as means + SEM. No significant differences between the two 
cAng-(1-7)-treated groups were measured. Statistically significant differences were found 
between vehicle-treated rats (s.c, n=13) compared to the cAng-(1-7)-treated rats (500 μg/kg/d, 
s.c., n=14) and to the cAng-(1-7) treated rats (500 μg/kg/d alzet, n=14) on days 22-50. 















Fig. 4. CAng-(1-7) improves somatosensory and sensory motor deficits after stroke.  
Data from a forelimb placement test between (0) and maximally impaired (12) are presented 
as means + SEM. No significant differences were measured between both cAng-(1-7)-treated 
groups. Statistically significant differences were found between vehicle, (s.c., n=13) compared 
with cAng-(1-7) (500 μg/kg/d, s.c., n=14) or cAng-(1-7) (500 μg/kg/d alzet, n=14) as indicated 
by asterisks in the figure, *p < 0.05; ** p < 0.01; *** p < 0.001. 
 
Fig. 5. CAng-(1-7) improves rat’s functioning in the body swing test delta after stroke.  
Data are represented as means + SEM. No significant differences between the cAng-(1-7)-
treated groups were observed. Statistically significant differences were measured between 
vehicle (s.c., n=13) compared with cAng-(1-7) (500 μg/kg/d s.c., n=14) or with cAng-(1-7) 
(500 μg/kg/d, alzet, n=14) as indicated by the asterisks in the figure, *p < 0.05; ** p < 0.01; 
*** p < 0.001.  
 
Fig. 6ABCDE. CAng-(1-7) increases capillary density after stroke.  
Figure A, B, C and D are representative images from the parietal lobe of 13 (A,C) and 14 (B,D) 
animals. The scale bar in Figures A, B, C, D represents a distance of 50 µm. A, SMA staining 
of vehicle-treated animal. B, SMA staining of cAng-(1-7)-treated animal. C, Factor 8 staining 
of vehicle-treated animal. D, Factor 8 staining of cAng-(1-7)-treated animal. E, capillary 
density ratio (ipsilateral/contralateral hemisphere) in treated rats compared to vehicle control 
on day 50. Data are presented as percentage relative to the left undamaged hemisphere + SEM. 
Statistically significant difference were found between the cAng-(1-7)-treated group compared 
to the vehicle-treated control group as indicated by asterisks in the figure, ** p < 0.01. 
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